Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585616 | PMC |
| http://dx.doi.org/10.1016/j.lanwpc.2023.100927 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Good response with nivolumab and cabozantinib combination therapy in patients with metastatic collecting duct carcinoma with high expression of PD-L1, c-MET, and AXL.
CEN Case Rep
September 2025
Department of Urology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Collecting duct carcinoma (CDC) is a rare subtype of renal cell carcinoma with a poor prognosis. Moreover, despite various chemotherapeutic strategies and administration of several tyrosine kinase inhibitors for metastatic CDC, the outcomes remain unfavorable, with no established treatment. Herein, we report the cases of two patients with CDC who exhibited a good response to nivolumab and cabozantinib combination therapy.
View Article and Find Full Text PDFEfficacy of Immune Checkpoint Inhibitors in the Treatment for Head and Neck Cancer Patients: A Systematic Review and Network Meta-Analysis.
Oncol Res
September 2025
Department of Pathology, Changzhi Medical College, Changzhi, 046000, China.
Objectives: Checkpoint inhibitors have significantly improved outcomes in a number of malignancies. To determine the most effective course of treatment for head and neck squamous cell carcinoma (HNSCC), this systematic review evaluated the efficacy of several therapeutic approaches based on immune checkpoint inhibitors (ICIs).
Methods: A comprehensive evaluation of the literature was conducted, looking at randomized controlled trials (RCTs) that were published in Embase, PubMed, and the Cochrane Central Register of Controlled Trials since database establishment.
Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical Trial.
Am J Clin Oncol
September 2025
Department of Head and Neck-Endocrine Oncology.
Objectives: We report on the biomarker analyses focusing on neutrophil-to-lymphocyte ratios (NLR) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with combined cetuximab and nivolumab.
Methods: Data were obtained from a phase II trial (NCT03370276). Peripheral blood NLR was obtained at baseline (B-NLR) and on-treatment (OT-NLR; 1 mo from treatment initiation).
Survival patterns after perioperative treatment escalation and cystectomy for synchronous oligometastatic bladder cancer (M1a/M1b) - a population-based series.
Scand J Urol
September 2025
Department of Urology, Skåne University Hospital, Malmö, Sweden; Institution of Translational Medicine, Lund University, Malmö, Sweden.
Background: The role of cystectomy in synchronous oligometastatic bladder cancer is unclear.
Objective: To describe a population-based consecutive cohort with primary oligometastatic bladder cancer (M1a or M1b) treated with curative intent. Methods: Twenty consecutive patients with primary stage M1a or M1b bladder cancer subjected to induction chemotherapy and radical cystectomy 2013-2024 in the Southern healthcare region were identified in the Swedish National Register for Urinary Bladder Cancer.
Efficacy of postoperative immunotherapy on MPM patients after CRS + HIPEC: A single-center retrospective study based on propensity score matching.
Int J Cancer
September 2025
Department of Peritoneal Oncology, Cancer Center of Beijing Tsinghua Changgung Hospital & School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
To investigate the efficacy of postoperative immunotherapy in patients with malignant peritoneal mesothelioma (MPM) after cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). The clinical data of 160 MPM patients who underwent CRS + HIPEC at our center from April 2015 to February 2024 were retrospectively analyzed. All patients received postoperative chemotherapy and were divided into the Chemo-only group and the Immunotherapy group according to whether they received postoperative immunotherapy or not.
View Article and Find Full Text PDF